Modulation Of Stem And Progenitor Cells, And Bleomycin-induced Pulmonary Fibrosis By Spiperone In Mice
Skurikhin EG, Pershina OV*, Khmelevskaya ES, Ermakova NN, Reztsova AM, Krupin VA and Dygai AM
Department of Pathophysiology and Regenerative Medicine, Federal State Institution “Scientific-Research Institute of Pharmacology” Siberian Branch of the Academy of Medical Sciences, st. Lenin, 3, Tomsk, Russia
- *Corresponding Author:
- Pershina OV
Department of Pathophysiology and Regenerative Medicine
Federal State Institution “Scientific-Research Institute of
Pharmacology” Siberian Branch of the
Academy of Medical Sciences, st. Lenin, 3, Tomsk, Russia 634028
E-mail: [email protected]
Received date: April 28, 2014; Accepted date: May 31, 2014; Published date: June 02, 2014
Citation: Skurikhin EG, Pershina OV, Khmelevskaya ES, Ermakova NN, Reztsova AM, et al. (2014) Modulation of Stem and Progenitor Cells and Bleomycininduced Pulmonary Fibrosis by Spiperone in Mice. J Stem Cell Res Ther 4:210. doi:10.4172/2157-7633.1000210
Copyright: © 2014 Skurikhin EG, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Bleomycin-induced lung inflammation and fibrosis were assessed in a model of idiopathic pulmonary fibrosis in C57BL/6 mice and effect of spiperone on histopathological lung indicators, hematopoietic (HSC) and mesenchymal (MSC) stem cells and progenitor cells was characterized. Spiperone is a selective antagonist of D2 dopamine receptors which disturbs dopamine mediation. Hematoxylin and eosin staining showed spiperone decreased alveolar epithelial edema, exudation and infiltration of the alveoli walls and lumen by inflammatory cells (neutrophils, macrophages, plasma cells) after bleomycin instillation. Picrofuchsin staining by Van Gieson revealed spiperone decreases the area of connective tissue in the lung fibrotic phase of pulmonary fibrosis. ELISA assay determined the decrease levels of collagen type I, hydroxyproline and total collagen in lung homogenate after spiperone treatment. Number of “long-term” HSCs (Lin- Sca-1+c-Kit+CD34-), «short-term” HSCs (Lin-Sca-1+c-Kit+CD34+), hematopoietic progenitor cells and MSC-like cells in lung with pneumofibrosis decreased after spiperone treatment. This spiperone effect we connect to the violation of immature bone marrow cells migration. Additionally, spiperone inhibited clonal activity of hematopoietic (CFU-GEMM, CFU-G) and mesenchymal (CFU-F) progenitor of bone marrow, blood and lungs. An additional feature of the spiperone action was the ability to decrease the capacity of self-renewal and MSCs differentiation activity into adipocytes, osteoblasts, chondrocytes and fibroblast cells. Thus, a selective antagonist D2 of dopamine receptors spiperone can act as a potential antifibrotic agent for the treatment of toxic pulmonary fibrosis. The overall conclusion was that the neurotropic agent spiperone is able to influence the stem and progenitor cells in lung pathology effectively.